In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

With pulmonary arterial hypertension (PAH) being a disease of a progressive nature, noninvasive parameters are sought to help follow the patients' course and detect deterioration. The 6-minute walk ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...

Now, it’s worth noting Stock Advisor’s total average return is 969 % — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...